Dupilumab for asthma has been accepted for FDA review as an add-on maintenance treatment in adults and adolescents (12 and up) with moderate to severe persistent asthma. Dupilumab (brand name is Dupixent) is currently approved for patients with moderate to severe eczema, it was approved March 2017. Dupilumab (Dupixent) for Atopic Dermatitis (Eczema) Sufferers Dupilumab […]
Dupilumab for Nasal Polyps
Since the release of dupilumab for atopic dermatitis, studies are currently underway to investigate dupilumab for nasal polyps, asthma and a host of other conditions. Dupilumab is a human monoclonal antibody against interleukin 4 and 13. A study published in JAMA titled “Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis […]